Galena Biopharma Inc
Change company Symbol lookup
Select an option...
GALE Galena Biopharma Inc
BAC Bank of America Corp
SASR Sandy Spring Bancorp Inc
ICFI ICF International Inc
FEI First Trust MLP and Energy Income Fund Common
MNE BlackRock Muni NY Intermediate Duration Fund
SPXX Nuveen S&P 500 Dynamic Overwrite Fund
STND Standard Financial Corp
SSYS Stratasys Ltd
SSUMY Sumitomo Corp
Go

Health Care : Biotechnology | Small Cap BlendCompany profile

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Closing Price
$0.688
Day's Change
0.0437 (6.78%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.7201
Day's Low
0.62
Volume
(Light)
Volume:
1,867,000
10-day average volume:
2,382,492
1,867,000
  • Prev Close
    0.6443
  • Today's Open
    0.628
  • Day's Range
    0.62-0.7201
  • Avg Vol (10-day)
    2.4M
  • Last (time)
    4:00p ET 02/24/17
  • Last (size)
    2
  • 52-Wk Range
    0.62 - 49.80
    LowHigh
  • (06/20/16 - 02/24/17)
    10.97%
  • 210.8%
  • Market Cap
    24.6M
  • Shares Outstanding
    35.8M
  • -2.32
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • 1.9
  • 6.11
  • --

Latest News

February 21, 2017
5:29 pm ET
Globe Newswire
7:55 am ET
PR Newswire
February 20, 2017
3:29 pm ET
BusinessWire
February 16, 2017
2:09 pm ET
BusinessWire
10:10 am ET
Globe Newswire
February 15, 2017
8:54 pm ET
BusinessWire
7:35 pm ET
Globe Newswire
7:29 pm ET
BusinessWire
February 14, 2017
6:27 pm ET
BusinessWire
6:16 pm ET
BusinessWire
February 13, 2017
4:30 pm ET
Globe Newswire
12:43 pm ET
PR Newswire
10:10 am ET
BusinessWire
February 10, 2017
8:06 pm ET
BusinessWire
5:49 pm ET
PR Newswire
1:03 pm ET
BusinessWire
12:48 pm ET
PR Newswire
12:14 pm ET
BusinessWire
February 09, 2017
5:06 pm ET
BusinessWire
3:40 pm ET
BusinessWire
February 08, 2017
9:01 am ET
MarketWatch
8:34 am ET
MarketWatch
8:30 am ET
Globe Newswire
February 07, 2017
4:14 pm ET
Globe Newswire
8:45 am ET
PR Newswire
February 06, 2017
9:09 am ET
MarketWatch
9:09 am ET
MarketWatch
7:30 am ET
MarketWatch
7:14 am ET
MarketWatch
7:05 am ET
Globe Newswire
January 31, 2017
5:00 pm ET
Globe Newswire
January 13, 2017
7:35 am ET
PR Newswire
January 05, 2017
7:05 am ET
Globe Newswire
December 28, 2016
9:04 am ET
MarketWatch
8:58 am ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2017 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by SunGard.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by , Computrade Systems, Inc.,, , and

Copyright © 2017. All rights reserved.